ATS 2020 Advance Program

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM D9 LUNG CANCER RISK ASSESSMENT: CLINICAL MODELS X MOLECULAR BIOMARKERS Assemblies on Thoracic Oncology; Clinical Problems; Environmental, Occupational and Population Health 8:45 a.m. - 10:45 a.m. Target Audience Pulmonary clinicians, thoracic surgeons, radiologists, and public health workers including those involved in organizing/running CT screening programs, or those referring to CT screening programs, as well as those interested in chemoprevention. Objectives At the conclusion of this session, the participant will be able to: • more appropriately refer individuals for CT/lung cancer screening; • improve the patient outcomes of CT screening; • apply risk assessment knowledge from the lung cancer screening realm to effect risk reduction beyond the screening realm.Targeted smoking cessation, and chemo-phyto-prevention uptake could be measured. That risk assessment is central to clinical medicine and public health practice is undisputed. For early detection and prevention of lung cancer, focusing on those at highest risk is imperative. The evolution of trans-platform ‘omics plus prior knowledge, has been coupled to vastly augmented instrumentation sensitivity. The combination now allows for detection of trace signatures of early lung carcinogenesis in humans non-invasively. This session will review clinical models, and several biomarkers in the genomics, transcriptomics, and metabolomics realms that are now, and/or will soon become, part of the clinicians armamentarium in earlier detection and pre-emption of this still lethal cancer. Chairing: S.D. Spivack, MD, MPH, Bronx, NY V.S. Nair, MSCR, MD, Seattle, WA P.P. Massion, MD, Nashville, TN 8:45 What Model Performance Standards Should We Shoot For, and Where Are We Now? P.J. Mazzone, MPH, MD, Cleveland, OH 9:00 How Do Clinical Models Perform in Risk Assessment? M.K. Gould, MD, MS, Pasadena, CA 9:15 Evolution of the Bronchial Genome Classifier J. Beane, PhD, Boston, MA 9:35 Circulating Extracellular Vesicles as Lung Cancer Biomarkers P. Nana-Sinkam, MD, Richmond, VA 9:55 Exhaled Breath-Based Risk Assessment Using MicroRNAs and Metabolomics S.D. Spivack, MD, MPH, Bronx, NY 10:15 Lung Cancer Genomics Leveraged for Risk Assessment V.S. Nair, MSCR, MD, Seattle, WA 10:30 Distillation P.P. Massion, MD, Nashville, TN BASIC • BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM D10 THE EVOLUTION OF INHALATION: THE BIOLOGIC, PHYSICAL, AND POLICY IMPLICATIONS OF VAPING AND OTHER NOVEL DEVICES Assembly on Behavioral and Health Services Research 8:45 a.m. - 10:45 a.m. Target Audience All providers caring for patients who vape or smoke; policy makers and clinical and basic science researchers. Objectives At the conclusion of this session, the participant will be able to: • understand and describe the biologic pathways through which ENDS and heat-not-burn devices may cause harm to the user; • more appropriately counsel patients and the public about the potential health effects of ENDS and the ATS 2020 • Philadelphia, PA 130 WEDNESDAY • MAY 20